<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zheng SS</submitter><funding>Xiamen Municipal Bureau of Science and Technology</funding><funding>Natural Science Foundation of Fujian Province</funding><pagination>1499-1515</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11461582</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(5)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Chromobox Homolog 1 (CBX1) plays a crucial role in the pathogenesis of numerous diseases, including the evolution and advancement of diverse cancers. The role of CBX1 in pan-cancer and its mechanism in hepatocellular carcinoma (HCC), however, remains to be further investigated.&lt;h4>Methods&lt;/h4>Bioinformatics approaches were harnessed to scrutinize CBX1's expression profile, its association with tumor staging, and its potential impact on patient outcomes across various cancers. Single-cell RNA sequencing data facilitated the investigation of CBX1 expression patterns at the individual cell level. The CBX1 expression levels in HCC and adjacent non-tumor tissues were quantified through Real-Time Polymerase Chain Reaction (RT-PCR), Western Blotting (WB), and Immunohistochemica</pubmed_abstract><journal>Hepatology international</journal><pubmed_title>CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.</pubmed_title><pmcid>PMC11461582</pmcid><funding_grant_id>3502Z20224ZD1081</funding_grant_id><funding_grant_id>2022J05332</funding_grant_id><pubmed_authors>Wu JF</pubmed_authors><pubmed_authors>Huang C</pubmed_authors><pubmed_authors>Zhang D</pubmed_authors><pubmed_authors>Zheng SS</pubmed_authors><pubmed_authors>Wu WX</pubmed_authors><pubmed_authors>Hu JW</pubmed_authors><pubmed_authors>Zhang BH</pubmed_authors></additional><is_claimable>false</is_claimable><name>CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.</name><description>&lt;h4>Background&lt;/h4>Chromobox Homolog 1 (CBX1) plays a crucial role in the pathogenesis of numerous diseases, including the evolution and advancement of diverse cancers. The role of CBX1 in pan-cancer and its mechanism in hepatocellular carcinoma (HCC), however, remains to be further investigated.&lt;h4>Methods&lt;/h4>Bioinformatics approaches were harnessed to scrutinize CBX1's expression profile, its association with tumor staging, and its potential impact on patient outcomes across various cancers. Single-cell RNA sequencing data facilitated the investigation of CBX1 expression patterns at the individual cell level. The CBX1 expression levels in HCC and adjacent non-tumor tissues were quantified through Real-Time Polymerase Chain Reaction (RT-PCR), Western Blotting (WB), and Immunohistochemica</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2025-04-26T20:12:52.358Z</modification><creation>2025-04-06T16:23:27.767Z</creation></dates><accession>S-EPMC11461582</accession><cross_references><pubmed>38769286</pubmed><doi>10.1007/s12072-024-10696-0</doi></cross_references></HashMap>